Canada - New discovery may revolutionize treatment of amyotrophic lateral sclerosis (ALS)Neurodegenerative disease managementLou Gehrigs disease managementMedical healthcare research.doi:10.1108/ijhcqa.2012.06225baa.003MCB UP LtdInternational Journal of Health Care Quality Assurance...
These are in-vitro diagnostic or medical devices for deciding on medicinal product use that: (i) identify patients most likely/unlikely to benefit; (ii) identify patients likely to be at high risk of serious side effects; and/or, (iii) monitor patient response to enable treatment tuning to ...
FDA approves axicabtagene ciloleucel for second-line treatment of large B-cell lymphoma On April 1, 2022, the Food and Drug Administration approved axicabtagene ciloleucel (Yescarta, Kite Pharma, Inc.) for adult patients with large B-cell lymphoma (LBCL) that is refractory to first-line...
The FDA's decision was based on a single phase 2 clinical trial of 137 ALS patients that found people who took Amylyx's drug, which will be sold under the nameRelyvrio,lived about 10 months longerthan those who didn't receive it. The drug also appeared to delay hospitalizations. The m...
(Jin and Zhong2023; Mead et al.2023). The development of disease-modifying gene therapies is a priority in ALS.Tofersenis an intrathecally administered antisense oligonucleotide and is the first approved treatment for ALS in adults with a confirmed mutation in the SOD1 gene (Blair2023c). ...
Treatment optimization may be enabled by new evidence on treatment combinations and the upcoming availability of new topical/oral formulations of existing medications. Various novel therapeutic interventions are being investigated, some based on the increased understanding of rosacea’s pathophysiology. 1 Int...
However, treatment of cardiomyocytes with a calcium chelator, 1,2-Bis(2-aminophenoxy)ethane-N,N,N’, N’-tetraacetic acid tetrakis(acetoxymethyl ester), did not affect autosis (23), suggesting that calcium may not be involved in autosis. Interestingly, the interaction between Na+,K+-ATPase ...
ALSFRS-R is reproducible and easily administered but at the same time is subjective and affected by symptomatic treatment (e.g. anticholinergic drugs for sialorrhea)23. Furthermore, about a seventh of patients with ALS of a pooled clinical trial database (PRO-ACT) in the placebo group has be...
Respiratory syncytial virus (RSV) is a significant cause of lower respiratory tract infection in infants and elderly. To understand the evolution of neutralizing epitopes on the RSV glycoprotein (G) and fusion (F) proteins, we conducted a multi-year surv
On June 2, 1941, at the age of 37, baseball player Lou Gehrig succumbed to amyotrophic lateral sclerosis (ALS), a progressive muscle degeneration disease. Today, nearly 80 years following his death, scientists are still searching for the root cause—and an effective treatment—for the condition...